Pharmacokinetics of L/105, a new rifamycin, in rats and dogs, after oral administration.
The absorption and tissue distribution of a new rifamycin, L/105, which chemically is 4-deoxy-4'-methylpyrido [1',2'-1,2]imidazo [5,4 C] rifamycin SV, were studied in rats after oral administration of 100 mg/kg. This study showed that L/105, contrary to what was observed for rifampicin, was practically not absorbed: neither serum nor significant tissue levels were evidenced. Also in dogs, after oral administration of L/105 in a single dose (25 mg/kg) and a multiple dosage (10 mg/kg/day, for 8 days), no traces of the compound were detected in the serum. The elimination was investigated in the rat: the highest recovery of L/105 (more than 50% of the administered dose) was in feces after 72 h, hardly any traces were found in urine.
D000284:Administration, Oral; D000818:Animals; D004285:Dogs; D005243:Feces / Q000032:analysis; D007700:Kinetics; D008297:Male; D051381:Rats; D011919:Rats, Inbred Strains; D012294:Rifamycins / Q000378:metabolism*; D000078262:Rifaximin; D013045:Species Specificity; D013997:Time Factors
D012294:Rifamycins; D000078262:Rifaximin